Third nerve palsy following intravitreal anti-VEGF therapy for bilateral neovascular age-related macular degeneration.
Micieli
Jonathan A
JA
Santiago
Patrick
P
Brent
Michael H
MH
D020533:Angiogenesis Inhibitors / Q000009:adverse effects*; D000911:Antibodies, Monoclonal / Q000009:adverse effects; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D001763:Blepharoptosis / Q000139:chemically induced*; D020256:Choroidal Neovascularization / Q000188:drug therapy*; D006801:Humans; D058449:Intravitreal Injections; D008268:Macular Degeneration / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D015840:Oculomotor Nerve Diseases / Q000139:chemically induced*; D009886:Ophthalmoplegia / Q000139:chemically induced*; D000069579:Ranibizumab; D019233:Retreatment; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab; D000069579:Ranibizumab